‘Heroes Of CRISPR’: Vivid Yarn And Lessons Learned From A Scientific Leap Ahead

(Courtesy of NIH)

(Courtesy of NIH)

It’s being billed as biotech’s Battle Royale, an East Coast-West Coast conflict over stakes that may amount to hundreds of millions of dollars, playing out in the arcane arena of U.S. patent law.

For the story on the legal fight that kicked into full gear this week, you can read the Washington Post’s Carolyn Johnson: Control of CRISPR, Biotech’s Most Promising Breakthrough, Is In Dispute.

Everybody loves a good fight, but the import of CRISPR for humankind is not the conflict or the money. It’s that this new gene-editing technology is indisputably transforming biological research around the world, speeding up discoveries in areas from cancer to crop science.

“Medical breakthroughs often emerge from completely unpredictable origins.”

– Eric Lander

So what are the roots of this bio-revolution? And what can we learn from how it was discovered? Eric Lander explores the CRISPR backstory in a vivid scientific yarn just out in the journal Cell, available free online for the next two weeks.

Lander co-led the Human Genome Project and is now the director of the Cambridge-based genomics giant The Broad Institute, which is involved in the CRISPR patent dispute. He’s also a leading science storyteller, from popular MIT lectures on introductory biology to surely one of the most riveting episodes of The Moth ever made.

The Broad’s rivals in the patent dispute may have different versions of specific chapters (Update, 1/26: Understatement! The article unleashed a major backlash online) but Lander also draws general lessons from the CRISPR back-story:

The most important is that medical breakthroughs often emerge from completely unpredictable origins. The early heroes of CRISPR were not on a quest to edit the human genome — or even to study human disease. Their motivations were a mix of personal curiosity (to understand bizarre repeat sequences in salt-tolerant microbes), military exigency (to defend against biological warfare), and industrial application (to improve yogurt production).

The history also illustrates the growing role in biology of “hypothesis-free” discovery based on big data. The discovery of the CRISPR loci, their biological function, and the tracrRNA all emerged not from wet-bench experiments but from open-ended bioinformatic exploration of large-scale, often public, genomic datasets. “Hypothesis-driven” science of course remains essential, but the 21st century will see an increasing partnership between these two approaches. Continue reading

Further Reading

Breaking News: Genzyme To Sell Genetic Testing Unit for $925M

Genzyme is selling its genetic testing division

Genzyme, the beleaguered Cambridge biotech firm trying to fight off a takeover bid, will sell its genetic testing division to Lab Corp. of America Holdings for $925 million, The Boston Globe reports.

Genzyme’s genetic testing business unit operates nine laboratories in the United States, including one in Westborough that employs 500 people, a Genzyme spokeswoman said. The purchase agreement calls for North Carolina-based LabCorp to buy those facilities along with the business, she added.

In 2009, the genetic testing business had revenues of $371 million, said Genzyme, which had total 2009 revenues of $4.5 billion.

Genzyme recently rejected a takeover offer by French pharmaceutical firm Sanofi-Aventis SA, but apparently France’s largest drug maker will not be deterrred. Bloomberg reports that Sanofi has arranged $10 billion in underwritten loans to back its bid.

And closer to home, here’s a bit of smart analysis from WBUR’s election blog on how Genzyme’s troubles could impact the gubernatorial race (specifically, how the company’s recent announcement that it would layoff 1,000 employees throws water on Gov. Patrick’s Life Sciences Initiative.)